398 studies found for:    "Lupus Erythematosus, Systemic"
Show Display Options
Rank Status Study
1 Terminated Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Intervention: Drug: epratuzumab
2 Completed Anti-CD20 in Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention: Drug: Rituximab
3 Completed Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome
Conditions: Lupus Erythematosus, Systemic;   Sjogren's Syndrome
Intervention: Drug: Dehydroepiandrosterone
4 Unknown  Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus
Conditions: Lupus Erythematosus, Systemic;   Arthritis, Rheumatoid
Intervention:
5 Terminated Physical Therapy for Systemic Lupus Erythematosus (SLE)
Conditions: Lupus Erythematosus, Systemic;   SLE
Intervention: Behavioral: Physical Therapy or Relaxation Therapy
6 Completed Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: Rituxan (rituximab);   Biological: filgrastim;   Drug: methylprednisolone;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: autologous hematopoietic stem cell transplantation
7 Unknown  Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention: Procedure: Hematopoietic Cell Transplantation
8 Completed Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Conditions: Lupus Erythematosus, Systemic;   Lupus Nephritis
Interventions: Drug: CTLA4-IgG4m (RG2077);   Drug: Cyclophosphamide
9 Enrolling by invitation An Open-label Study to Evaluate the Long-term Safety of MEDI-546, a Product Under Investigation for the Treatment of Systemic Lupus Erythematosus, in Adults
Condition: Lupus Erythematosus, Systemic
Intervention: Biological: MEDI-546
10 Completed A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic
Interventions: Drug: 1 mg/kg CNTO 136;   Drug: 4 mg/kg CNTO 136;   Drug: 10 mg/kg CNTO 136;   Drug: Placebo
11 Completed Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
Conditions: Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Interventions: Drug: R932333;   Drug: Placebo
12 Completed Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
Conditions: Lupus Nephritis;   Lupus Erythematosus, Systemic
Intervention: Drug: tacrolimus
13 Unknown  Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention:
14 Active, not recruiting Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention:
15 Completed Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
Conditions: Lupus Erythematosus, Systemic;   Adverse Effects
Interventions: Genetic: Polymorphism Analysis;   Drug: Cyclophosphamide;   Other: Pharmacokinetic analysis
16 Active, not recruiting Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Biological: Prevenar® and Pneumo23®;   Biological: Placebo, Pneumo23®
17 Recruiting Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Mycophenolate Mofetil;   Drug: Hydroxychloroquine or Chloroquine;   Drug: Prednisone
18 Completed Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention: Drug: SBI-087
19 Recruiting Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Atacicept 75 milligram (mg);   Drug: Atacicept 150 mg;   Drug: Placebo
20 Active, not recruiting Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
Conditions: Immune System Diseases;   Autoimmune Diseases;   Lupus Erythematosus, Systemic;   Skin and Connective Tissue Diseases;   Connective Tissue Disease
Interventions: Biological: CDP7657;   Other: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years